Growth hormone reduced HIV-related visceral fat

November 2008
Hem/Onc Today;11/10/2008, Vol. 9 Issue 20, p40
The article discusses findings of a randomized, double-blind, placebo-controlled trial that was conducted by researchers from Massachusetts General Hospital in Boston, which examined the efficacy of low-dose growth hormone on body composition, glucose and cardiovascular factors as observed among patients with HIV and relative growth hormone deficiency. It has been revealed that low-dose growth hormone therapy may decrease visceral fat and truncal obesity associated with HIV and relative growth hormone deficiency.


Related Articles

  • Yukmijihwang-tang for the treatment of xerostomia in the elderly: study protocol for a randomized, double-blind, placebo-controlled, two-center trial. Gajin Han; Jae-Woo Park; Seok-Jae Ko; Jihee Son; Jongki Seon; Juyeon Kim; Seulki Kim; Inkwon Yeo; Bongha Ryu; Jinsung Kim // Trials;2013, Vol. 14 Issue 1, p1 

    Background: Xerostomia, a subjective sense of dry mouth, is not generally regarded a disease despite its high prevalence among the elderly, and therefore continues to impair affected patients' quality of life. In traditional Korean medicine, 'Yin-Deficiency' has been implicated in the...

  • Is there a place for placebo controlled trials of antiepileptic drugs? Shorvon, S.D.; Espir, M.L.E.; Steiner, T.J.; Dellaportas, C.I.; Rose, F. Clifford // British Medical Journal (Clinical Research Edition);11/9/1985, Vol. 291 Issue 6505, p1328 

    Examines the possibility of a placebo controlled trials on antiepileptic drugs in Great Britain. Uncertainty on the role of anticonvulsant drugs on epileptics; Impact of epileptic seizures on the psychology and social behavior of epileptics; Natural history of epilepsy.

  • Withholding Proven Treatment in Clinical Research. Huston, Patricia; Peterson, Robert // New England Journal of Medicine;9/20/2001, Vol. 345 Issue 12, p912 

    Editorial. Discusses the ethics of placebo-controlled clinical trials. Role of the Declaration of Helsinki; Need for scientific and ethical justification of the use of placebos.

  • An Evaluation of Arbaprostil at Multiple Doses for the Treatment of Acute Duodenal Ulcer: A Randomized Double Blind Placebo-Controlled International Trial. Euler, A. R.; Krawiec, J.; Odes, H.; Gilat, T.; Garcia, L.; Rachmilewitz, D.; Gabryelewicz, A.; Gibinski, K.; Bass, D.; Barbara, L.; Porro, G. Bianchi; Lazzaroni, M.; Kirchmayer, S.; Nago-Nago, A.; Popiela, T.; Kulig, J.; Roca, M.; Hagenmuller, F.; Bergemann, W.; Schryver, M. // American Journal of Gastroenterology;Feb1990, Vol. 85 Issue 2, p145 

    Six hundred and thirty patients were enrolled in a randomized double-blind placebo-controlled trial evaluating two arbaprostil dosages (25 µg and 50 µg) qid for 4 wk for the treatment of acute duodonal ulcers. The healing rates in the placebo, 25-µg, and 50-µg treatment groups were...

  • Is the Placebo Powerless? Hróbjartsson, Asbjørn; Gøtzsche, Peter C. // New England Journal of Medicine;05/24/2001, Vol. 344 Issue 21, p1594 

    Background: Placebo treatments have been reported to help patients with many diseases, but the quality of the evidence supporting this finding has not been rigorously evaluated. Methods: We conducted a systematic review of clinical trials in which patients were randomly assigned to either...

  • Importance of Placebo Effect in Cough Clinical Trials. Eccles, Ron // Lung;Feb2010 Supplement 1, Vol. 188, p53 

    Cough is a unique symptom because, unlike sneeze and other symptoms, it can be under voluntary control and this complicates clinical trials on cough medicines. All over-the-counter cough medicines (OTC) are very effective treatments because of their placebo effect. The placebo effect is enhanced...

  • The Powerful Placebo Effect in Cough: Relevance to Treatment and Clinical Trials. Eccles, Ron // Lung;Feb2020, Vol. 198 Issue 1, p13 

    Interest in the placebo effect of medicines has developed from the use of placebo treatments as controls in clinical trials into a whole new area of research around how placebos fit into a psychosocial model of therapeutics. The large placebo effect associated with cough medicines is both a...

  • Rifaximin Treatment in Hepatic Encephalopathy. Bass, Nathan M.; Mullen, Kevin D.; Sanyal, Arun; Poordad, Fred; Neff, Guy; Leevy, Carroll B.; Sigal, Samuel; Sheikh, Muhammad Y.; Beavers, Kimberly; Frederick, Todd; Teperman, Lewis; Hillebrand, Donald; Huang, Shirley; Merchant, Kunal; Shaw, Audrey; Bortey, Enoch; Forbes, William P. // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1071 

    Background: Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the treatment of acute hepatic encephalopathy, but its efficacy for prevention of the disease has not been...

  • Limitations of Using Outcomes in the Placebo Arm of a Clinical Trial of Benign Prostatic Hyperplasia to Quantify Those in the Community. Roberts, Rosebud O.; Lieber, Michael M.; Jacobson, Debra J.; Girman, Cynthia J.; Jacobsen, Steven J. // Mayo Clinic Proceedings;Jun2005, Vol. 80 Issue 6, p759 

    OBJECTIVES: To quantify potential biases that may occur when placebo arms of clinical trials are used to characterize the natural history of disease and to compare incidence rates of benign prostatic hyperplasia (BPH) outcomes in community-dwelling men with outcomes in the placebo arm of a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics